Regcon Holdings Company Profile
What is the competitive landscape for REGCON HOLDINGS
REGCON HOLDINGS has fifty-five approved drugs.
Summary for Regcon Holdings
| US Patents: | 0 |
| Tradenames: | 49 |
| Ingredients: | 49 |
| NDAs: | 55 |
Drugs and US Patents for Regcon Holdings
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Regcon Holdings | LACOSAMIDE | lacosamide | TABLET;ORAL | 208308-004 | Mar 17, 2022 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Regcon Holdings | LACOSAMIDE | lacosamide | SOLUTION;INTRAVENOUS | 214301-001 | Apr 7, 2022 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Regcon Holdings | FLECAINIDE ACETATE | flecainide acetate | TABLET;ORAL | 210683-003 | Sep 16, 2020 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Regcon Holdings | CETIRIZINE HYDROCHLORIDE | cetirizine hydrochloride | TABLET;ORAL | 218895-001 | Oct 3, 2024 | OTC | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
